• Rapamycin (Sirolimus): Mechanistic Precision for Translation

  2026-06-03

  Explore how Rapamycin (Sirolimus) acts as a keystone inhibitor of mTOR signaling, enabling translational researchers to dissect and modulate cellular pathways in cancer, immunology, and mitochondrial disease models. This article bridges mechanistic depth with actionable guidance, referencing new discoveries in mitophagy and differentiation, and highlights APExBIO’s validated Rapamycin for advanced experimental workflows.

• Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz

  2026-06-03

  This study reveals how Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 through TRIM3 inhibition. The findings highlight a new pathway for targeting RA-FLS proliferation and inflammation, offering a promising avenue for RA intervention and selective estrogen receptor modulator studies.

• MG53 E3 Ligase Drives Cyclin D1 Degradation to Suppress Tumo

  2026-06-02

  This study uncovers MG53 as a previously unrecognized E3 ubiquitin ligase that directly targets cyclin D1 for proteasomal degradation, thereby arresting cell cycle progression and suppressing tumor growth. The findings highlight a mechanistic link between MG53 deficiency, cyclin D1 accumulation, and poor cancer outcomes, informing new strategies for targeting cyclin D1 turnover in refractory malignancies.

• Phosphotungstic Acid Negative Stain Solution (2%): Precision

  2026-06-02

  Explore how Phosphotungstic Acid Negative Stain Solution (2%) enables advanced visualization of viral glycan vulnerabilities, empowering researchers to decipher macromolecular architecture and inform antiviral strategy. This cornerstone guide delivers scientific depth and distinct workflow insights.

• Angiotensin I: Cross-Domain Insights from Cardiovascular to

  2026-06-01

  Explore Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as more than a cardiovascular research tool. This article connects its biochemical role to emerging viral mechanisms, offering advanced guidance for renin-angiotensin system research and antihypertensive drug screening.

• CD44-Driven Copper Accumulation Activates Ly6Chi Macrophages

  2026-06-01

  This study elucidates a mechanistic link between CD44-mediated copper accumulation and the activation of pro-inflammatory Ly6Chi macrophages in ulcerative colitis. The findings reveal that targeting CD44 or copper metabolism can modulate macrophage activation and oxidative stress, highlighting new potential avenues for therapeutic intervention.

• Tunicamycin: Applied Workflows for N-Glycosylation Inhibitio

  2026-05-31

  Tunicamycin from APExBIO is the gold-standard N-glycosylation inhibitor, enabling robust modeling of endoplasmic reticulum (ER) stress and inflammation suppression in cellular and in vivo systems. This article delivers data-driven workflow enhancements, troubleshooting guidance, and actionable insights—translating recent breakthroughs into reproducible, high-impact experimental design.

• Paroxetine Mesylate: Molecular Targeting Beyond SSRI Activit

  2026-05-30

  Explore Paroxetine Mesylate as a selective serotonin reuptake inhibitor with unique multi-kinase and cytochrome P450 inhibition, expanding its value in research beyond classic antidepressant roles. This article delivers a rigorous molecular analysis and practical assay insight for advanced translational workflows.

• Dihydrotestosterone (DHT): Protocols for AR and EGFR Pathway

  2026-05-29

  Dihydrotestosterone (DHT) unlocks precise control over androgen receptor and growth factor signaling in cancer, neurodegeneration, and muscle research. This guide translates recent breakthroughs into actionable protocols, troubleshooting guidance, and comparative insights for optimizing your research with APExBIO’s DHT.

• Z-VAD-FMK: Pan-Caspase Inhibitor for Apoptosis Pathway Resea

  2026-05-29

  Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor widely used to dissect apoptotic signaling in both in vitro and in vivo studies. Its established specificity for caspase blockade enables precise apoptosis inhibition in research, as demonstrated by robust evidence in immune and cancer models.

• Esflurbiprofen Blocks SERT-nNOS for Rapid Antidepressant Eff

  2026-05-28

  The reference study introduces esflurbiprofen as a novel fast-onset antidepressant, acting by disrupting the SERT-nNOS interaction in the dorsal raphe nucleus. This mechanistic advance over conventional SSRIs provides a new avenue for antidepressant development with improved therapeutic onset.

• BMS-777607: Advanced c-Met Inhibitor Workflows for Platelet

  2026-05-28

  BMS-777607, a potent c-Met inhibitor from APExBIO, is redefining experimental precision in both cancer metastasis modeling and hiPSC-derived platelet workflows. This article details protocol enhancements, application bridges, and troubleshooting tactics, drawing from the latest literature to maximize reproducibility and yield.

• Calcitriol and VDR Signaling: Bench to Reproductive Biology

  2026-05-27

  Explore how Calcitriol, a key 1,25-dihydroxy vitamin D3 metabolite, advances reproductive research by unlocking new mechanistic insights into endometrial decidualization and immune modulation. This article uniquely connects advanced VDR pathway findings to practical assay and workflow design.

• FK866 (APO866): Precision NAMPT Inhibition in Cancer Researc

  2026-05-27

  FK866 (APO866) is redefining cancer biology workflows by selectively targeting NAD biosynthesis with nanomolar potency. Recent reference studies demonstrate how combining FK866 with PARP inhibitors leverages metabolic vulnerabilities in RAS/PI3K-mutant ovarian and hematologic cancers, unlocking new avenues for selective cytotoxicity and resistance management.

• Humanized Gs-Coupled DREADD Enables Safer Neural Circuit Mod

  2026-05-26

  This study introduces a fully humanized Gs-coupled DREADD (hM3Ds), addressing immunogenicity concerns and demonstrating functional equivalence to rodent models. The innovation expands the translational potential of chemogenetic neuromodulation, with clear implications for both research and clinical applications.

15812 records 1/1055 page Next 12345 下5页 Last page